Do you have any questions?
Don't hesitate to contact us. We are happy to answer your questions.
Meet us at the 18th International Conference on Malignant Lymphoma (ICML)
Meet our medical team to find out more about our clinical program and CAR-T therapies this June 17- 20 in Lugano, Switzerland
Meet us at the 18th International Conference on Malignant Lymphoma (ICML)
Meet our medical team to find out more about our clinical program and CAR-T therapies this June 17- 20 in Lugano, Switzerland
Oral presentations at 18-ICML, 2025
Interim Results of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Where: Room B
When: Wednesday June 18 at 5:30 p.m.
Session: 5:00 p.m. – 6:00 p.m.: New cellular therapies
Tandem CD20-19-Directed Non-Cryopreserved CAR-T Cells– Zamtocabtagene Autoleucel (Zamto-cel) - in Patients with Relapsed/Refractory CNS Lymphoma in DALY II US study
Where: Room A
When: Saturday June 21 at 9:00 a.m.
Session 17: 8:15 a.m. – 09:30 a.m.: CNS Lymphomas
We are looking forward to seeing you at 18-ICML, 2025
The 18-ICML will take place at the Lugano Convention Centre, Palazzo dei Congressi, Switzerland. You will find us at the Miltenyi Biomedicine booth in the Marquee Parco Ciani. Visit us to speak to our medical team about our clinical program and open trials.
Exhibition opening hours:
Tuesday, 17 June, 2:00 p.m. - 6:00 p.m.
Wednesday, 18 June, 9:00 a.m. - 6:00 p.m.
Thursday, 19 June, 9:00 a.m. - 6:00 p.m.
Friday, 20 June, 9:00 a.m. - 6:00 p.m.
See the 18-ICML, 2025 detailed program
View the 18-ICML program here
Latest resources from Miltenyi Biomedicine
View recent posters, presentations and press releases
Tandem CD20-CD19-Directed Non-Cryopreserved CAR T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)
Tandem Meetings – Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR | presentation slides
Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (zamto-cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
ASH24 | presentation slides
Miltenyi Biomedicine will share positive interim results from DALY II USA at the American Society of Hematology (ASH) Annual Meeting
ASH 2024 | press release
Bispecific anti-CD20/19 CAR-T – zamtocabtagene autoleucel for relapsed/refractory DLCBL – interim analysis results of DALY-II-USA study
EHA2023 Hybrid Congress | poster information
Interim analysis of a Phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR T cell therapy zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA, NCT04792489)
Tandem Meetings of ASTCT and CIBMTR 2023 I presentation slides
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
EHA 2022 | poster download
Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial
ASH 2022 | presentation abstract
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
ASH 2022 | presentation abstract
Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
ASH 2022 | presentation abstract
